RxDoctor Payments DataLook up a doctor →

Cindy Marrow, MD

Adult Medicine · Fredericksburg, VANPI 1407842263

Payments from drug & device makers

$10,843in general payments, 2019–2025

Across 728 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$801
  • Pfizer$765
  • AstraZeneca$703
  • Otsuka America Pharmaceutical, Inc.$657
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,72199%
  • Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,843 in reported general payments places this provider in the 95th percentile of 32 adult medicine providers in Virginia.

See all adult medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$322,614
Medicare patients
751
Services billed
4,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$177,071
EliquisApixaban101$89,243
JardianceEmpagliflozin62$87,545
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$37,021
MounjaroTirzepatide22$36,437
FarxigaDapagliflozin Propanediol31$30,145
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$26,139
MyrbetriqMirabegron19$17,010
JanuviaSitagliptin Phosphate17$14,257
Spiriva RespimatTiotropium Bromide17$13,135
Breo ElliptaFluticasone/Vilanterol12$11,595
Tresiba Flextouch U-100Insulin Degludec12$7,498
Atorvastatin Calcium655$6,886
SynthroidLevothyroxine Sodium94$6,336
Levothyroxine Sodium420$6,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,029$177,071141 claims
Boehringer IngelheimJardiance, Spiriva Respimat$231$100,68079 claims
PfizerEliquis$765$89,243101 claims
GSKTrelegy Ellipta, Breo Ellipta$308$48,61654 claims
Lilly USA, LLCMounjaro$801$36,43722 claims
AstraZenecaFarxiga, Symbicort$703$33,97742 claims
Astellas Pharma US IncMyrbetriq$242$17,01019 claims
MerckJanuvia$212$14,25717 claims
AbbVieSynthroid$1,658$6,33694 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 32 adult medicine providers in Virginia.

Other adult medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →